Literature DB >> 9820292

Interferon beta therapy for multiple sclerosis.

D E Goodkin1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820292     DOI: 10.1016/S0140-6736(98)00057-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  16 in total

1.  The end of the affair--public health medicine 1974-2002.

Authors:  Peter Sim
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

2.  Beta interferon, NICE, and rationing.

Authors:  David Kernick
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

3.  Are GP leaders scared of sex?

Authors:  Penny Watson
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

4.  RCGP 'virtual genetics' group meeting: 'the use of the family history in primary care'.

Authors:  Rhydian Hapgood; Michael Modell
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

5.  Defining and cultivating the virtues.

Authors:  Peter Toon
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

6.  An oral history of general practice 4: changing practice.

Authors:  Rona Ferguson; Graham Smith
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

7.  Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.

Authors:  R B Forbes; A Lees; N Waugh; R J Swingler
Journal:  BMJ       Date:  1999-12-11

Review 8.  Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.

Authors:  D S Goodin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 9.  The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.

Authors:  Ceri J Phillips
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.

Authors:  Andrew R Schneider; Youssef Sari
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.